Baseline characteristics of veterans with AML treated with frontline venetoclax combinations
| Patient characteristics . | All patients (N = 452) . | Psychiatric disorder (n = 157) . | SUD (n = 34) . | Psychiatric + SUD (n = 49) . | Neither (n = 212) . | P value . |
|---|---|---|---|---|---|---|
| Age, median (IQR) | 74.3 (71.2-78.5) | 74.0 (70.9-77.9) | 70.8 (69.3-73.3) | 72.2 (68.0-74.8) | 75.6 (72.9-80.4) | <.001 |
| <65 y, n (%) | 34 (7.5) | 15 (9.6) | 5 (14.7) | 8 (16.3) | 6 (2.8) | |
| 65-74 y, n (%) | 184 (40.7) | 65 (41.4) | 22 (64.7) | 26 (53.1) | 71 (33.5) | |
| ≥75 y, n (%) | 234 (51.8) | 77 (49.0) | 7 (20.6) | 15 (30.6) | 135 (63.7) | |
| Male, n (%) | 445 (98.5) | 154 (98.1) | 34 (100) | 49 (100) | 208 (98.1) | .659 |
| Race/ethnicity, n (%) | .008 | |||||
| White | 343 (75.9) | 129 (82.2) | 28 (82.4) | 32 (65.3) | 154 (72.6) | |
| Black | 47 (10.4) | 9 (5.7) | 5 (14.7) | 12 (24.5) | 21 (9.9) | |
| Hispanic | 23 (5.1) | 8 (5.1) | 1 (2.9) | 1 (2.0) | 13 (6.1) | |
| Other/unknown | 39 (8.6) | 11 (7.0) | 0 (0.0) | 4 (8.2) | 24 (11.3) | |
| Income in dollars, median (IQR) | 28 806 (16 773-40 092) | 28 716 (17 412-36 876) | 33 005.22 (18 500- 44 334) | 24 341.40 (12 444-33 792) | 28 812 (18 000-42 500) | .112 |
| Rurality, n (%)∗ | .745 | |||||
| Urban | 291 (64.4) | 97 (61.8) | 21 (61.8) | 33 (67.3) | 140 (66.0) | |
| Rural | 153 (33.8) | 60 (38.2) | 13 (38.2) | 16 (32.7) | 70 (33.0) | |
| Unknown | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.9) | |
| Tobacco dependence, n (%) | 126 (27.9) | 38 (24.2) | 19 (55.9) | 29 (59.2) | 40 (18.9) | <.001 |
| Frail†, n (%) | 329 (72.8) | 134 (85.4) | 24 (70.6) | 42 (85.7) | 129 (60.8) | <.001 |
| Therapy-related AML, n (%) | 27 (6.0) | 12 (7.6) | 2 (5.9) | 2 (4.1) | 11 (5.2) | .867 |
| Prior MDS/CMML/MPN, n (%) | 162 (35.8) | 50 (31.8) | 16 (47.0) | 19 (38.8) | 77 (36.3) | .695 |
| Prior treatment with DNMTi, n (%) | 56 (12.4) | 22 (14.0) | 8 (23.5) | 5 (10.2) | 21 (9.9) | .388 |
| ELN 2017 risk, n (%) | .461 | |||||
| Favorable | 27 (6.0) | 13 (8.3) | 0 (0.0) | 4 (8.2) | 10 (4.7) | |
| Intermediate | 100 (22.1) | 35 (22.3) | 9 (26.5) | 11 (22.4) | 45 (21.2) | |
| Adverse | 274 (60.6) | 97 (61.8) | 19 (55.9) | 29 (59.2) | 129 (60.8) | |
| Bone marrow blast >30%, n (%) | 250 (55.3) | 85 (54.1) | 17 (50.0) | 27 (55.1) | 121 (57.1) | .71 |
| FLT3-ITD/TKD, n (%) | 43 (9.5) | 13 (8.3) | 0 (0.0) | 5 (10.2) | 25 (11.8) | .016 |
| NPM1 mutation, n (%) | 27 (6.0) | 12 (7.6) | 0 (0.0) | 2 (4.1) | 13 (6.1) | .088 |
| IDH1 mutation, n (%) | 24 (5.1) | 8 (5.1) | 0 (0.0) | 4 (8.2) | 12 (5.7) | .081 |
| IDH2 mutation, n (%) | 41 (9.1) | 17 (10.8) | 4 (11.8) | 5 (10.2) | 15 (7.1) | .081 |
| TP53 mutation, n (%) | 56 (12.4) | 17 (10.8) | 10 (29.4) | 7 (14.3) | 22 (10.4) | .016 |
| ASXL1 mutation, n (%) | 66 (14.6) | 24 (15.3) | 3 (8.8) | 5 (10.2) | 34 (16.0) | .556 |
| RUNX1 mutation, n (%) | 67 (14.8) | 28 (17.8) | 2 (5.9) | 5 (10.2) | 32 (15.1) | .249 |
| Patient characteristics . | All patients (N = 452) . | Psychiatric disorder (n = 157) . | SUD (n = 34) . | Psychiatric + SUD (n = 49) . | Neither (n = 212) . | P value . |
|---|---|---|---|---|---|---|
| Age, median (IQR) | 74.3 (71.2-78.5) | 74.0 (70.9-77.9) | 70.8 (69.3-73.3) | 72.2 (68.0-74.8) | 75.6 (72.9-80.4) | <.001 |
| <65 y, n (%) | 34 (7.5) | 15 (9.6) | 5 (14.7) | 8 (16.3) | 6 (2.8) | |
| 65-74 y, n (%) | 184 (40.7) | 65 (41.4) | 22 (64.7) | 26 (53.1) | 71 (33.5) | |
| ≥75 y, n (%) | 234 (51.8) | 77 (49.0) | 7 (20.6) | 15 (30.6) | 135 (63.7) | |
| Male, n (%) | 445 (98.5) | 154 (98.1) | 34 (100) | 49 (100) | 208 (98.1) | .659 |
| Race/ethnicity, n (%) | .008 | |||||
| White | 343 (75.9) | 129 (82.2) | 28 (82.4) | 32 (65.3) | 154 (72.6) | |
| Black | 47 (10.4) | 9 (5.7) | 5 (14.7) | 12 (24.5) | 21 (9.9) | |
| Hispanic | 23 (5.1) | 8 (5.1) | 1 (2.9) | 1 (2.0) | 13 (6.1) | |
| Other/unknown | 39 (8.6) | 11 (7.0) | 0 (0.0) | 4 (8.2) | 24 (11.3) | |
| Income in dollars, median (IQR) | 28 806 (16 773-40 092) | 28 716 (17 412-36 876) | 33 005.22 (18 500- 44 334) | 24 341.40 (12 444-33 792) | 28 812 (18 000-42 500) | .112 |
| Rurality, n (%)∗ | .745 | |||||
| Urban | 291 (64.4) | 97 (61.8) | 21 (61.8) | 33 (67.3) | 140 (66.0) | |
| Rural | 153 (33.8) | 60 (38.2) | 13 (38.2) | 16 (32.7) | 70 (33.0) | |
| Unknown | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.9) | |
| Tobacco dependence, n (%) | 126 (27.9) | 38 (24.2) | 19 (55.9) | 29 (59.2) | 40 (18.9) | <.001 |
| Frail†, n (%) | 329 (72.8) | 134 (85.4) | 24 (70.6) | 42 (85.7) | 129 (60.8) | <.001 |
| Therapy-related AML, n (%) | 27 (6.0) | 12 (7.6) | 2 (5.9) | 2 (4.1) | 11 (5.2) | .867 |
| Prior MDS/CMML/MPN, n (%) | 162 (35.8) | 50 (31.8) | 16 (47.0) | 19 (38.8) | 77 (36.3) | .695 |
| Prior treatment with DNMTi, n (%) | 56 (12.4) | 22 (14.0) | 8 (23.5) | 5 (10.2) | 21 (9.9) | .388 |
| ELN 2017 risk, n (%) | .461 | |||||
| Favorable | 27 (6.0) | 13 (8.3) | 0 (0.0) | 4 (8.2) | 10 (4.7) | |
| Intermediate | 100 (22.1) | 35 (22.3) | 9 (26.5) | 11 (22.4) | 45 (21.2) | |
| Adverse | 274 (60.6) | 97 (61.8) | 19 (55.9) | 29 (59.2) | 129 (60.8) | |
| Bone marrow blast >30%, n (%) | 250 (55.3) | 85 (54.1) | 17 (50.0) | 27 (55.1) | 121 (57.1) | .71 |
| FLT3-ITD/TKD, n (%) | 43 (9.5) | 13 (8.3) | 0 (0.0) | 5 (10.2) | 25 (11.8) | .016 |
| NPM1 mutation, n (%) | 27 (6.0) | 12 (7.6) | 0 (0.0) | 2 (4.1) | 13 (6.1) | .088 |
| IDH1 mutation, n (%) | 24 (5.1) | 8 (5.1) | 0 (0.0) | 4 (8.2) | 12 (5.7) | .081 |
| IDH2 mutation, n (%) | 41 (9.1) | 17 (10.8) | 4 (11.8) | 5 (10.2) | 15 (7.1) | .081 |
| TP53 mutation, n (%) | 56 (12.4) | 17 (10.8) | 10 (29.4) | 7 (14.3) | 22 (10.4) | .016 |
| ASXL1 mutation, n (%) | 66 (14.6) | 24 (15.3) | 3 (8.8) | 5 (10.2) | 34 (16.0) | .556 |
| RUNX1 mutation, n (%) | 67 (14.8) | 28 (17.8) | 2 (5.9) | 5 (10.2) | 32 (15.1) | .249 |
CMML, chronic myelomonocytic leukemia; DNMTi, DNA methyltransferase inhibitor; ELN, European LeukemiaNet; IQR, interquartile range; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms.
Defined by the Rural-Urban Commuting Areas system, which takes into account population density and how close a community is linked socioeconomically to larger urban centers.
Defined as ≥0.2 using the electronic Veterans Affairs Frailty Index calculated based on 31 comorbidities/potential deficits.